Thermo Fisher Scientific Inc. $TMO Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% in the third quarter, HoldingsChannel.com reports. The firm owned 216,638 shares of the medical research company’s stock after selling 5,041 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.8% of Douglas Lane & Associates LLC’s portfolio, making the stock its 11th biggest holding. Douglas Lane & Associates LLC’s holdings in Thermo Fisher Scientific were worth $146,242,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of TMO. BlackRock Inc. bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $15,501,867,000. State Street Corp boosted its holdings in Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after acquiring an additional 229,630 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at about $1,974,561,000. Bank of America Corp DE purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,428,731 shares of the medical research company’s stock worth $1,407,328,000 after buying an additional 13,728 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Michael Shafer sold 25,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc Casper sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Up 1.1%

Thermo Fisher Scientific stock traded up $7.33 during trading hours on Friday, reaching $659.31. The company had a trading volume of 482,660 shares, compared to its average volume of 2,244,217. The firm has a market cap of $243.78 billion, a price-to-earnings ratio of 35.44, a P/E/G ratio of 2.77 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $694.33. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a 50-day moving average price of $625.73 and a 200 day moving average price of $540.54.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the company earned $4.28 earnings per share. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Analyst Ratings Changes

TMO has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $720.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, September 25th. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. BMO Capital Markets lowered Thermo Fisher Scientific to a “market perform” rating in a report on Wednesday, September 9th. Barclays raised their price target on shares of Thermo Fisher Scientific from $650.00 to $750.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Piper Sandler started coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an “overweight” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $634.86.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.